|
|
|
|
pmid:
|
Salcedo M et al. |
The marine sphingolipid-derived compound ES 285 triggers an atypical cell death pathway. |
2007 |
Apoptosis |
pmid:17191124
|
Stokvis E et al. |
A more sensitive MS detector does not obviously lead to a more sensitive assay: experiences with ES-285. |
2004 |
Biomed. Chromatogr. |
pmid:15273982
|
Schöffski P et al. |
Spisulosine (ES-285) given as a weekly three-hour intravenous infusion: results of a phase I dose-escalating study in patients with advanced solid malignancies. |
2011 |
Cancer Chemother. Pharmacol. |
pmid:21465314
|
Cuadros R et al. |
The marine compound spisulosine, an inhibitor of cell proliferation, promotes the disassembly of actin stress fibers. |
2000 |
Cancer Lett. |
pmid:10754202
|
FabiÅ¡Ãková M et al. |
Total synthesis and the anticancer activity of (+)-spisulosine. |
2016 |
Carbohydr. Res. |
pmid:27693911
|
Merrill AH |
Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics. |
2011 |
Chem. Rev. |
pmid:21942574
|
Xu K et al. |
A highly anti-selective asymmetric Henry reaction catalyzed by a chiral copper complex: applications to the syntheses of (+)-spisulosine and a pyrroloisoquinoline derivative. |
2012 |
Chemistry |
pmid:22907874
|
Kowluru A |
Deoxysphingolipids: β-cell, beware of these new kids on the block. |
2014 |
Diabetes |
pmid:24651803
|
Zuellig RA et al. |
Deoxysphingolipids, novel biomarkers for type 2 diabetes, are cytotoxic for insulin-producing cells. |
2014 |
Diabetes |
pmid:24379346
|
Chen BS et al. |
Diastereoselective synthesis and bioactivity of long-chain anti-2-amino-3-alkanols. |
2011 |
Eur J Med Chem |
pmid:21955681
|
Sánchez AM et al. |
Spisulosine (ES-285) induces prostate tumor PC-3 and LNCaP cell death by de novo synthesis of ceramide and PKCzeta activation. |
2008 |
Eur. J. Pharmacol. |
pmid:18343365
|
Rotthier A et al. |
Characterization of two mutations in the SPTLC1 subunit of serine palmitoyltransferase associated with hereditary sensory and autonomic neuropathy type I. |
2011 |
Hum. Mutat. |
pmid:21618344
|
Massard C et al. |
Phase I dose-escalating study of ES-285 given as a three-hour intravenous infusion every three weeks in patients with advanced malignant solid tumors. |
2012 |
Invest New Drugs |
pmid:22215532
|
Vilar E et al. |
A phase I dose-escalating study of ES-285, a marine sphingolipid-derived compound, with repeat dose administration in patients with advanced solid tumors. |
2012 |
Invest New Drugs |
pmid:20820909
|
den Brok MW et al. |
Development and validation of a liquid chromatography-ultraviolet absorbance detection assay using derivatisation for the novel marine anticancer agent ES-285 x HCl [(2S,3R)-2-amino-3-octadecanol hydrochloride] and its pharmaceutical dosage form. |
2003 |
J Chromatogr A |
pmid:14661748
|
Stokvis E et al. |
Quantitative analysis of ES-285, an investigational marine anticancer drug, in human, mouse, rat, and dog plasma using coupled liquid chromatography and tandem mass spectrometry. |
2003 |
J Mass Spectrom |
pmid:12794877
|
Duan J and Merrill AH |
1-Deoxysphingolipids Encountered Exogenously and Made de Novo: Dangerous Mysteries inside an Enigma. |
2015 |
J. Biol. Chem. |
pmid:25947379
|
Esaki K et al. |
L-Serine Deficiency Elicits Intracellular Accumulation of Cytotoxic Deoxysphingolipids and Lipid Body Formation. |
2015 |
J. Biol. Chem. |
pmid:25903138
|
Maraschiello C et al. |
Phenylisothiocyanate and dansyl chloride precolumn derivatizations for the high-performance liquid chromatography analysis of the antitumoral agent ES-285 in dog plasma. |
2003 |
J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. |
pmid:12798159
|